Anti-inflammatory androstane derivative

• US 7,629,335 B2
• Filed: 07/06/2006
• Issued: 12/08/2009
• Est. Priority Date: 08/05/2000
• Status: Expired due to Term

• Current Assignee: GlaxoSmithKline Intellectual Property Management Limited (GSK plc)
• Original Assignee: Glaxo Group Limited (GSK plc)
• Inventors: Biggadike, Keith, Coote, Steven John, Nice, Rosalyn Kay
• Primary Examiner(s): Badio; Barbara P
• Application Number:
  US11/428,853
• Publication Number:
  US 20070027128A1
• Time in Patent Office: 1,251 Days
• Field of Search: 540/114, 514/172
• US Class Current: 514/172
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: A61P 11/02 Nasal agents, e.g. decongestants
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 5/44 Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Abstract

According to one aspect of the invention, there is provided a compound of formula (I)

and solvates thereof. There are also provided compositions containing the compound, processes for preparing it, and its use in therapy.

Claims

1. A pharmaceutical composition comprising dry powder particles which are between 1 and 10 microns in size and which comprise the compound of formula (I)

2. The pharmaceutical composition of claim 1, further comprising lactose.

3. A dry powder inhaler comprising a pharmaceutical composition comprising the compound of formula (I)

4. The dry powder inhaler of claim 3 further comprising lactose.